Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Withdrawn 1Recruiting 1

Sponsor Class

OTHER 5OTHER_GOV 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 5Esophageal Neoplasms 4Carcinoma, Non-Small-Cell Lung 3Small Cell Lung Carcinoma 2Pathologic Complete Response 2Fallopian Tube Neoplasms 2Adenocarcinoma of Lung 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Thymoma 1Testicular Neoplasms 1Recurrence 1Ovarian Neoplasms 1Non-squamous Cell Non-Small Cell Lung Cancer 1Non-Squamous Non-Small Cell Lung Cancer 1Nasopharyngeal Carcinoma 1Lung Neoplasms 1HER2 Positive Breast Cancer 1Endometrial Neoplasms 1EGFR Positive Non-small Cell Lung Cancer 1Carcinoma, Ovarian Epithelial 1

Interventions

pertuzumab 2Trastuzumab 2Docetaxel 2Carboplatin 2Epirubicin 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER_GOV × Pathologic Complete Response × Carboplatin × Clear all
NCT06927180 2025-06-23

SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

Henan Cancer Hospital

Phase 2 Recruiting
180 enrolled
Breast

Pathologic Complete Response, Breast Neoplasms

NCT05474690 2024-02-26

A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer

Henan Cancer Hospital

Phase 3 Withdrawn
Breast

Pathologic Complete Response, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡